Señalización JAK / STAT
Subcategorías de "Señalización JAK / STAT"
Se han encontrado 356 productos de "Señalización JAK / STAT"
lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Fórmula:C16H25N5OSForma y color:SolidPeso molecular:335.468AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Fórmula:C20H28FN7Pureza:98%Forma y color:SolidPeso molecular:385.48PF-06263276
CAS:PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).Fórmula:C31H31FN8O2Pureza:98%Forma y color:SolidPeso molecular:566.63Tyk2-IN-3
CAS:Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).Fórmula:C25H24N6O3S2Pureza:98%Forma y color:SolidPeso molecular:520.63JAK1/TYK2-IN-4
CAS:JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].Fórmula:C17H23N7OForma y color:SolidPeso molecular:341.41Tyk2-IN-17
CAS:Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].Fórmula:C20H20F2N8OForma y color:SolidPeso molecular:426.42JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFórmula:C17H20N6OPureza:98.81%Forma y color:SolidPeso molecular:324.38JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Fórmula:C28H39N3O3Forma y color:SolidPeso molecular:465.63(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Fórmula:C16H20N6OPureza:98%Forma y color:SolidPeso molecular:312.37JAK2-IN-9
CAS:Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.
Fórmula:C20H24N6O2SPureza:98%Forma y color:SolidPeso molecular:412.51Ref: TM-T79581
Producto descatalogadoJAK-IN-34
CAS:JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,
Fórmula:C27H26N6OPureza:98%Forma y color:SolidPeso molecular:450.53JAK1-IN-11
CAS:JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.
Fórmula:C26H36N6O4SPureza:98%Forma y color:SolidPeso molecular:528.67JAK1-IN-10
CAS:JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
Fórmula:C15H17N7Pureza:98%Forma y color:SolidPeso molecular:295.34STAT3-IN-18
CAS:STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and
Fórmula:C18H24Cl2N2O6PtPureza:98%Forma y color:SolidPeso molecular:630.38DPP
CAS:DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating
Fórmula:C36H40Cl2N2O10PtPureza:98%Forma y color:SolidPeso molecular:926.7JAK-IN-27
CAS:JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM
Fórmula:C20H21F2N7OPureza:98%Forma y color:SolidPeso molecular:413.42
